Physician profile
Iman Doostan
NPI 1508216730
$2,436.90
in general payments reported to CMS, 2019-2025
20 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.62 · 2022: $477 · 2023: $1,040 · 2024: $725 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297 · Education: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,296.83 |
| Education | $646.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $349.96 | 2023-2024 | Jakafi |
| Seagen INC. | $317.35 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $294.27 | 2023-2025 | Calquence, Lynparza, Tagrisso |
| Aveo Pharmaceuticals, INC. | $210.90 | 2023-2024 | Fotivda |
| Sobi, INC | $197.99 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $180.98 | 2022-2024 | Ninlaro |
| Daiichi Sankyo INC. | $139.16 | 2022-2025 | Enhertu |
| Gilead Sciences, INC. | $124.99 | 2023 | Trodelvy |
| Janssen Biotech, INC. | $124.99 | 2022 | |
| Btg International INC. | $121.82 | 2023 | |
| G1 Therapeutics, INC. | $103.02 | 2023 | Cosela |
| Jazz Pharmaceuticals INC. | $55.40 | 2024 | |
| Eisai INC. | $33.18 | 2024 | |
| Regeneron Pharmaceuticals, INC. | $32.76 | 2023 | Libtayo |
| Beigene USA, INC. | $30.11 | 2024 | Brukinsa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $27.22 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $27.16 | 2024 | |
| Abbvie INC. | $25.21 | 2024 | |
| Lilly USA, LLC | $23.81 | 2024 | |
| Janssen Pharmaceuticals, INC | $16.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iman Doostan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.